

Submission Deadline: September 5th, 2018

Publication Date: November 2018

## Call for Papers

### Special Issue on Cancer Biomarker

In Journal of Cancer Therapy (JCT, ISSN Online: 2151-1942)

Detailed information about this journal: [Indexing](#), [Editorial Board](#), [Author's Guidelines](#)

A **cancer biomarker** refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

We sincerely welcome scholar and expert with relative academic backgrounds to submit original research paper or review paper to this special issue on **Cancer Biomarker**. Potential topics or areas include, but are not limited to:

- BRCA1 and BRCA2 in ovarian cancer
- Braf V600E mutation in melanoma
- EGFR-targeted therapies
- HER2 expression in breast cancer
- PSA screening for prostate cancer
- Predictive cancer biomarkers
- Biomarkers for diagnosis and prognosis

#### Submission Methods:

Submit a paper to this special issue or regular issue of our any journal via [Paper Submission System](#) or attach paper in an email sent to [submission.entrance1@scirp.org](mailto:submission.entrance1@scirp.org) (please indicate the name of our journal or special issue; any inquiry is also welcome).

Friendly tip: please bookmark this page in your web browser if you consider contributing to our journal or special issue in the near future.

#### Selected Published Articles in JCT journal



Check [More Articles](#) in JCT  
[Search Articles](#) in the whole site  
[All Journals](#) by subject

**[LKB1, A New Biomarker in Breast Cancer](#)**

Hanine Lattouf, Coralie Poulard, Isabelle Treilleux, Nader Hussein, Mona Diab-Assaf, Muriel Le Romancer

**[Correlation of Urinary Engrailed-2 Levels to Tumour Volume and Pathological Stage in Men Undergoing Radical Prostatectomy](#)**

Hardev Pandha, Saqib Javed, Prasanna Sooriakumaran, Simon Bott, Bruce Montgomery, Anthony Hutton, Christopher Eden, Christopher Eden, Stephen E. Langley, Richard Morgan

**[Markers for Diagnosis and Progression in Bladder Cancer](#)**

Josep M. Gaya, Juan Palou, Oscar Rodríguez, Humberto Villavicencio

**[The Prognostic Importance of EGFR and COX-2 Expression in Cervix Cancer Stages IIB-IVA](#)**

Parvin Adimi, Karina Dahl Steffensen, Doris Schledermann, Eva Rye Rasmussen, Anders Jakobsen

**[Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation](#)**

Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada

**[Estimation of PSA Half-Life Following Salvage Radiation Therapy](#)**

Ajay B. Patel, Katherine S. Tzou, Michael G. Heckman, Colleen S. Thomas, Richard J. Lee, Nitesh Paryani, Thomas M. Pisansky, Jennifer L. Peterson, Robert C. Miller, Stephen J. Ko, Laura A. Vallow, Steven J. Buskirk

**[The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy](#)**

Sarp K. Keskin, Asif Yildirim, Cengiz Canakci, Ismail Ulus, Ramazan Gokhan Atis, Turhan Caskurlu

Check [Other Open Special Issues](#)

Lung Cancer

Melanoma Research

Cancer Metastasis

Cancer Chemotherapy

Editorial Assistant



**Scientific Research**  
*Open Access*

**Journal of Cancer Therapy**  
ISSN Online: 2151-1942

---

JCT Editorial Office